BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25245468)

  • 1. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.
    Henriques de Figueiredo B; Zacharatou C; Galland-Girodet S; Benech J; De Clermont-Gallerande H; Lamare F; Hatt M; Digue L; De Mones del Pujol E; Fernandez P
    Strahlenther Onkol; 2015 Mar; 191(3):217-24. PubMed ID: 25245468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
    Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
    Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
    Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer.
    Choi W; Lee SW; Park SH; Ryu JS; Oh SJ; Im KC; Choi EK; Kim JH; Jung SH; Kim S; Ahn SD
    Radiother Oncol; 2010 Nov; 97(2):176-82. PubMed ID: 20855118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
    Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
    Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.
    Lin Z; Mechalakos J; Nehmeh S; Schoder H; Lee N; Humm J; Ling CC
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1219-28. PubMed ID: 18313529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
    Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
    Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.
    Yasuda K; Onimaru R; Okamoto S; Shiga T; Katoh N; Tsuchiya K; Suzuki R; Takeuchi W; Kuge Y; Tamaki N; Shirato H
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):142-7. PubMed ID: 22583608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
    Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.
    Hendrickson K; Phillips M; Smith W; Peterson L; Krohn K; Rajendran J
    Radiother Oncol; 2011 Dec; 101(3):369-75. PubMed ID: 21872957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
    Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry study of
    Li H; Xu D; Han X; Ruan Q; Zhang X; Mi Y; Dong M; Guo S; Lin Y; Wang B; Li G
    Clin Transl Oncol; 2018 Oct; 20(10):1329-1336. PubMed ID: 29623584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
    Schütze C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Zips D; Hessel F; Krause M; Thames H; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
    Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
    Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal dose escalation for prostate cancer using
    Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
    Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
    Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.